VX15-770-124: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have

Project: Research project

Project Details

StatusFinished
Effective start/end date3/1/167/31/18

Funding

  • Vertex Pharmaceuticals Incorporated
  • Vertex Pharmaceuticals Incorporated